Stephen Hindman
Cardiovascular Disease · Jackson, MSNPI 1508885435
Payments from drug & device makers
Across 137 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$806
- Boston Scientific$231
- Novartis$217
- Amgen$200
- Pfizer$175
- Merck$156
- plus $840 from 15 others
What the payments were for
- Food & beverage$2,626100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 49 | $806 |
| Boston Scientific | 3 | $231 |
| Novartis | 12 | $217 |
| Amgen | 14 | $200 |
| Pfizer | 12 | $175 |
| Merck | 9 | $156 |
| Boehringer Ingelheim | 5 | $121 |
| Lantheus Medical Imaging, Inc. | 1 | $120 |
| Johnson & Johnson | 6 | $111 |
| BTG International Inc. | 1 | $101 |
| Gilead | 5 | $77 |
| E.r. Squibb & Sons, L.L.C. | 5 | $67 |
| Bayer | 2 | $40 |
| AstraZeneca | 3 | $40 |
| Astellas Pharma US Inc | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $36 |
| Akcea Therapeutics, Inc. | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Abbott | 1 | $16 |
| GE HealthCare | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - STENTS$204
- Definity$120
- EKOSONIC$101
How this compares
$2,626 in reported general payments places this provider in the 35th percentile of 144 cardiovascular disease providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 63 | $50,377 |
| EliquisApixaban | 13 | $12,010 |
| Metoprolol Succinate | 32 | $548 |
| Spironolactone | 54 | $537 |
| Rosuvastatin Calcium | 43 | $470 |
| Atorvastatin Calcium | 33 | $313 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 15 | $241 |
| Furosemide | 49 | $236 |
| SotalolSotalol Hcl | 19 | $232 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 18 | $199 |
| Losartan Potassium | 13 | $185 |
| ClopidogrelClopidogrel Bisulfate | 29 | $174 |
| Carvedilol | 21 | $161 |
| Metoprolol Tartrate | 28 | $128 |
| Amlodipine Besylate | 27 | $125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $111 | $50,37763 claims |
| PfizerEliquis | $175 | $12,01013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Jackson
- James HaysJackson$782K
- Donny StokesJackson$277K
- James HaysJackson$65K
- James BenslerJackson$64K
- Michael HallJackson$54K
- James WarnockJackson$48K
- Tahsin QarqishJackson$39K
- Christopher LatourJackson$33K
- Kenneth MonahanJackson$31K
- Varun SardarJackson$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.